학술논문
P-45 EVALUATION OF THE ALBI SCORE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH YTTRIUM-90 (90Y)
Document Type
Article
Author
Source
Annals of Hepatology; February 2024, Vol. 29 Issue: 1, Number 1 Supplement 1
Subject
Language
ISSN
16652681
Abstract
Hepatocellular carcinoma (HCC) is the third cause of mortality worldwide. 10% of patients receive therapy with curative intent. There are loco-regional therapies to improve patient survival, such as (TACE) and radioembolization with Yttrium-90. There are prognostic scales, such as ALBI, to identify who will have a positive response to the treatment. We aimed to evaluate the potential of the ALBI index for HCC as a predictor of mortality and associate it with survival or complications in patients who received treatment with Yttrium-90, correlating with Child Pugh, MELD and MELD-NA scores.